Cargando…

Review of checkpoint immunotherapy for the management of non-small cell lung cancer

Checkpoint immunotherapy uses highly selective humanized monoclonal antibodies against checkpoint signals such as programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1). By blocking these receptors and signals, the immune system can be reactivated to fight the tumor. Immunoth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raju, Shine, Joseph, Ranjit, Sehgal, Sameep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074780/ https://www.ncbi.nlm.nih.gov/pubmed/30105218 http://dx.doi.org/10.2147/ITT.S125070

Ejemplares similares

Neoadjuvant immunotherapy in resectable non-small cell lung cancer at a checkpoint
por: Faltermeier, Claire M., et al.
Publicado: (2021)

Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
por: Sehgal, Kartik, et al.
Publicado: (2020)

Immune checkpoint inhibitors for every patient with non-small cell lung cancer? Update on immunotherapy in patients with lung cancer
por: Vansteenkiste, Johan F
Publicado: (2018)

Immunotherapy in Advanced Non-small Cell Lung Cancer Patients: Ushering Chemotherapy Through the Checkpoint Inhibitors?
por: Kanwal, Bushra, et al.
Publicado: (2018)

Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer
por: Li, Shumin, et al.
Publicado: (2020)

Immune checkpoints and immunotherapy in non-small cell lung cancer: Novel study progression, challenges and solutions
por: Ma, Lin-Rui, et al.
Publicado: (2021)

Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis
por: Alifu, Muyesar, et al.
Publicado: (2023)

Immunotherapy for Non-Small Cell Lung Cancer
por: Yoon, Sung Ho
Publicado: (2014)

Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
por: Krzyżanowska, Natalia, et al.
Publicado: (2022)

Precise Therapeutic Benefits and Underlying Mechanisms of Anlotinib Combined With Checkpoint Immunotherapy in Advanced Non-Small-Cell Lung Cancer
por: Xiang, Yi, et al.
Publicado: (2022)

Immunotherapy and the Treatment of Non–Small Cell Lung Cancer
por: Walker, Suzanne
Publicado: (2016)

Biomarkers of immunotherapy in non-small cell lung cancer
por: Wang, Lingling, et al.
Publicado: (2020)

Editorial: Community series in immunotherapy with checkpoint inhibitors for non-small cell lung cancer, colon cancer, and esophageal cancer, volume II
por: Li, Yueyi, et al.
Publicado: (2023)

Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non‐Small Cell Lung Cancer
por: Jia, Qingzhu, et al.
Publicado: (2020)

Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer
por: Yu, Xin, et al.
Publicado: (2021)

Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases
por: Yang, Guanqun, et al.
Publicado: (2022)

Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancer
por: Xu, Manyi, et al.
Publicado: (2023)

The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis
por: Wang, Chengdi, et al.
Publicado: (2019)

Immunotherapy in Cancer Management: A Literature Review of Clinical Efficacy of Pembrolizumab in the Non-small Cell Lung Cancer Treatment
por: Miquelotti, Luísa Biscaglia, et al.
Publicado: (2023)

Lung transplantation—breathing a new life
por: Mangukia, Chirantan, et al.
Publicado: (2021)

Targeted therapies and immunotherapy in non-small-cell lung cancer
por: Cortinovis, D, et al.
Publicado: (2016)

First line Immunotherapy for Non-Small Cell Lung Cancer
por: Nasser, Nicola J., et al.
Publicado: (2020)

Immunotherapy in oncogene addicted non-small cell lung cancer
por: McLean, Luke, et al.
Publicado: (2021)

Immunotherapy in non-small cell lung cancer: advancements and challenges
por: Zhou, Fei, et al.
Publicado: (2021)

Current status of immunotherapy for non-small cell lung cancer
por: Yang, Tao, et al.
Publicado: (2022)

Neoadjuvant immunotherapy in resectable non-small-cell lung cancer
por: Chen, Lanyi Nora, et al.
Publicado: (2023)

Immunotherapy through the Lens of Non-Small Cell Lung Cancer
por: Stanley, Robyn, et al.
Publicado: (2023)

Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer
por: Wang, Shang-Jui, et al.
Publicado: (2020)

Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front lines concurrently with chemoradiotherapy?
por: Hida, Toyoaki, et al.
Publicado: (2020)

CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer
por: Zhang, Man, et al.
Publicado: (2020)

CD66b as a prognostic and predictive biomarker in patients with non-small cell lung cancer treated with checkpoint blockade immunotherapy
por: Jain, Swati, et al.
Publicado: (2023)

The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review
por: Liu, Yu, et al.
Publicado: (2021)

Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
por: Hao, Yuxuan, et al.
Publicado: (2022)

Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer
por: Adderley, H., et al.
Publicado: (2020)

Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review
por: Wang, Yimin, et al.
Publicado: (2022)

Immunotherapy in inoperable stage III non-small cell lung cancer: a review
por: Jain, Natasha A, et al.
Publicado: (2019)

Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review
por: Gatteschi, Lavinia, et al.
Publicado: (2021)

Focal lung infiltrate complicating PD-1 inhibitor use: A new pattern of drug-associated lung toxicity?
por: Sehgal, Sameep, et al.
Publicado: (2016)

Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation?
por: Guo, Haoyue, et al.
Publicado: (2020)

Small cell transformation of non‐small cell lung cancer under immunotherapy: Case series and literature review
por: Imakita, Takuma, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cg6kmofha6jkhrmotsrkubfhni